RARE Ultragenyx Pharmaceutical


Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

ESG term mentions

In last year of SEC filings
CarbonCarbon FootprintCleanConservationEnvironmentEnvironmentalEnvironmental ProtectionGreenHazardLEEDLifecycleMaterialsMineralNatureOffsetOilPackagePackagingPandemicRaw MaterialsRegenerationRegenerativeSolarToxicWasteWindAccessBenefitsBlackCalifornia Consumer Privacy ActCollective BargainingCommunityCultureCustomerCyberCybersecurityData PrivacyData SecurityDeathDemographicDisabilityDiversityDiversity and InclusionDrug PricingEmployeeEmployee EngagementEmployee RetentionEngagementEthnicityGenderGeneral Data Protection RegulationHealth and SafetyHealth CareHealthcareHireHiringHuman CapitalHuman ResourcesIncidentInjuryPay EquityPay for PerformancePerquisitesPrivacyProduct QualityRecallRecruitRecruitmentReimbursementRetentionRetirementSafetySatisfactionSkillSkilledSkillsSocialSocietyStakeholderSupplierSupply ChainTalentTrainingUnionWorkforceWorkplace SafetyAnti-corruptionAntitrustAssessmentAssuranceAuditBonusBriberyChronicClassifiedClassified BoardClawbackCommitmentConflict of InterestCorporate GovernanceDepartment ofDirector ResignationESGEthicsExecutive CompensationExpertFraudGoalsGovernanceHedgingIncentiveIndependenceIndependentInnovationInnovativeInvestigationLawsuitLead Independent DirectorLeadershipLitigationLong-termMajorityMissionOverboardingOverseeOversightPerquisitePledgingPurposeQuality StandardR&DReputationReputationalResearch and DevelopmentResponsibilityResponsibleSelf-evaluationSpecial MeetingStockholder EngagementStockholder OutreachStrategySustainabilitySustainableTargetsTaxTenureTransparencyVoting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On June 24, 2021, Ultragenyx Pharmaceutical Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). As of the record date of April 26, 2021, 67,474,643 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. A total of 65,546,806 shares of the Company’s common stock were represented in person or by proxy at the Annual Meeting.

Proposal No. 1 – Election of Class II Directors

At the Annual Meeting, the Company’s stockholders elected the Class II director nominees below to the Company’s Board of Directors to hold office until the 2024 Annual Meeting of Stockholders or until their successors are elected. The votes on Proposal 1 were as follows:

Class I Director NomineesVotes ForVotes WithheldBroker Non-Votes
Deborah Dunsire, M.D.62,938,341893,8371,714,628
Michael Narachi46,632,51617,199,6621,714,628

Proposal No. 2 – Ratification of Selection of Independent Registered Accounting Firm

At the Annual Meeting, the Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021. The votes on Proposal 2 were as follows:

Votes ForVotes AgainstAbstentions

Proposal No. 3 – Advisory (Non-Binding) Vote to Approve Executive Compensation

At the Annual Meeting, the Company’s stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its “named executive officers” as described in the Proxy Statement. The votes on Proposal 3 were as follows:

Votes ForVotes AgainstAbstentionsBroker Non-Votes